Back

Factors associated to renin-angiotensin-aldosterone system inhibitors discontinuation or down-titration due to hyperkalaemia in patients with chronic cardiovascular conditions

26 August 2022 (08:00 - 19:30)
Organised by:
Congress Presentation Part of: Challenges in cardiovascular pharmacotherapy in patients who are older or with comorbidities Angiotensin-Renin-Bradykinin System ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Doctor Lidia Alcoberro

Bellvitge University Hospital, Hospitalet De Llobregat (Spain)

7 More presentations in this session

Presentation thumbnail
The use of warfarin as part of antithrombotic strategy after transcutaneous aortic valve replacement is not associated with better medium-term outcomes
Doctor J. Naser (Rochester, US)
Abstract Slides
Presentation thumbnail
Direct oral anticoagulants compared to vitamin K antagonists for the treatment of left ventricular thrombi
Doctor H. Morgan (London, GB)
Abstract Slides
Presentation thumbnail
Frailty and outcomes in octogenarians with atrial fibrillation treated with edoxaban: ESCAPE study
Doctor G. Denas (Motta Di Livenza, IT)
Abstract Slides
Presentation thumbnail
Oral anticoagulant therapy and decline of kidney function in elderly patients with non-valve atrial fibrillation: real world evidence data
Doctor G. Severini (Catanzaro, IT)
Abstract Slides
Presentation thumbnail
Previous antithrombotic therapy does not have an impact on the in-hospital mortality of patients with upper gastrointestinal bleeding
Doctor M. Hozman (Prague, CZ)
Abstract Slides

Access the full session

Session thumbnail
Challenges in cardiovascular pharmacotherapy in patients who are older or with comorbidities

The Event

Event poster

ESC Congress 2022

26 August - 29 August 2022
You may be interested in
thumbnail
Congress Presentation
RNA therapeutics for treatment of hypertension
thumbnail
Congress Session
Novel drug therapies in hypertension: new kids on the block
thumbnail
Congress Presentation
Investigating renal pathology in transgenic experimental rats: unraveling the effects of hypertension and heart failure

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources